Unexpected function of nucleoporin RanBP2 maintains BA homeostasis, protecting against liver toxicity.
2016 MCB Convocation Address by Dr. Deborah A. Paul
Thank you Dr. Sligar for the invitation to speak at the convocation, and thank you graduates for graduating so that I could have the opportunity to come back to one of my favorite places. I’m sure that most of you are here today with friends & family that have supported you in reaching this achievement. I want to talk to you today about someone who supported me, my brother Tim.
I was the shy, introverted scientist; Tim was the extroverted, artistic type. He wrote stories and poetry, and was quite a musician – playing many different instruments, though excelling at piano. He could walk into a room full of strangers and make everyone his friend. He was younger than me, but he supported me in so many ways, for example:
1. He was my date for 10 year high school class reunion – since he knew all my friends anyway;
2. He went with me when, in my mid-twenties, I was able to buy my 1st pair of toe shoes – having taken up ballet, which I always loved, a bit late in life. He knew how much it meant to me to have achieved this, and he wanted to be there.
3. He was also one of my biggest boosters for going back to get my PhD. After I had received my Masters in Biology here at Illinois, I wanted to go on for a PhD but I didn’t know what area of science I wanted to focus on. So I took a job at Abbott working on the Development side of R & D in Diagnostics, working on tests to detect Hepatitis B infection. After working a few years, I decided what I wanted to do for a PhD and took a leave of absence from Abbott to go back to grad school – combining biochemistry, virology and immunology to study Hepatitis B. Tim was so proud, and would introduce me as “my sister who’s working on her PhD.”
A few weeks before I left for grad school, Tim ended up in the hospital. He hadn’t been feeling well, and all of the lymph nodes all over his body had become enlarged. They ran all sorts of tests, but never figured out the problem. He started feeling better and was released.
A few years passed, and I was working on finishing up my PhD when I got the call that Tim had developed Pneumocystis carinii pneumonia – a type of pneumonia typically only found in immunosuppressed people. The doctors said this was consistent with a new disease that was popping up around the country – AIDS. Two weeks in ICU and a month in the hospital later, Tim survived the pneumonia that killed the majority of AIDs patients, but a few months later he developed cancer and started chemotherapy.
As I was finishing my PhD at this time, I had to decide what I wanted to do next. They had recently discovered the virus that causes AIDS – HIV, and Abbott was one of 5 companies that was to receive viral cultures from NIH to work on tests to protect the blood supply. All my work on Hepatitis B was the perfect set up to work on HIV – and I obviously had a lot of personal reasons to want to work on this virus. So I returned to Abbott, now in the research department, to do research for diagnostics tests for HIV. Unfortunately, Tim died 1 month later; he was 28 years old.
The other people in the department had already started work on an HIV Ab test that would be used to protect blood supply. I wanted to develop a test for the virus itself, and see if it was circulating in the bloodstream – even though the prevailing school of thought was that this would not be the case. I developed an ultrasensitive immunoassay and was able to demonstrate that HIV was indeed present in the bloodstream at various times throughout the disease, and this was significant because you could then:
1. Detect initial infection, which would have been useful for Tim’s 1st hospitalization when they could not determine what was wrong with him.
2. Detect viral re-emergence - since most patients, after becoming infected, entered an asymptomatic phase; but later something would trigger the virus to begin reproducing, which was a poor prognostic indicator, usually signaling the start of AIDS related diseases.
3. Monitor therapy – initial therapies were nucleoside analogues, and you could determine if the therapy was working by watching whether the level of circulating virus declined. However, most people also eventually developed drug resistance, so through monitoring for rising viral levels, you would then know to switch to a different therapy.
Abbott also had a Pharmaceutical division, and they were using computer-assisted drug design to develop small molecules that would inhibit the active site of the viral protease. However they needed a way to know which compounds were working. So we collaborated with them – since we were growing virus in culture and monitoring our cultures with the test I developed. We looked for compounds that would kill the virus in culture but leave the human cells healthy. This led to the initial protease inhibitors that were FDA approved and marketed. Though they were not in time for Tim, they changed the tide in the war against HIV infection so that AIDS was not a death sentence but a disease you could live with.
I spent 15 more years in the lab working on HIV and Hepatitis, then moved to business-side of things – though still supporting the work on HIV and Hepatitis. Later this also included work on the next generation nucleic acid tests using PCR to detect HIV, Hepatitis and other infectious diseases.
My career success then enabled me to honor Tim’s memory and his support of me by providing support to others through endowing a chair that will reside in the School of Molecular and Cellular Biology, with a joint appointment in the new College of Medicine, in the field of Infectious Disease and Immunology, in Tim’s name. I cannot tell you how happy it makes me to be able to do this.
In closing I would like to leave you with these thoughts: Do something that means something to you; that you are passionate about. If you do that, it will, by definition, make you personally successful. When you are able to, honor the support that you have received to achieve that success by giving back – and continue the circle of support.
Now – Go do great things ! Thank you.
~~ Deborah A. Paul, Ph.D. received her Masters in Biology from the University of Illinois in 1979.
Posted June 14, 2016
return to top
Emad Tajkhorshid receives Department of Defense Multidisciplinary University Research Initiative grant
In all, the Department of Defense awarded 23 studies a total of $162 million over the next five years for experimentation and analysis. Selected studies will benefit one of the Army Research Office, the Air Force Office of Scientific Research, or the Office of Naval Research.
“Over the past 30 years, the DoD’s MURI program has resulted in significant capabilities for our military forces and opened up entirely new lines of research,” Melissa L. Flagg, deputy assistant secretary of defense for research, said in a press release. “Examples include advances in laser frequency combs that have become the gold standard in frequency control for precision in navigation and targeting; atomic and molecular self-assembly projects that have opened new possibilities for nano-manufacturing; and the field of spintronics, which emerged from a MURI award on magnetic materials and devices research.”
Associate Professor Karen Sears Receives Two Prestigious Awards
Graduate Student and Postdoctoral Fellowships
The School, and particularly the departments and labs, are proud of the awardees' accomplishments and would like to encourage incoming students and postdoctoral scholars to apply for these opportunities.
Ruth L. Kirschstein National Research Service Award (NRSA): Fellowships aim to enrich the research training of promising predoctoral students by providing individualized, mentored research experience. Applicants must propose an integrated research plan and a dissertation research project that meet the guidelines of the participating NIH Institutes and Centers. The NRSA award provides up to 6 years of support for research and clinical training including stipends, tuition and fees, and institutional allowance. The fellowship is designed to clearly enhance the individual’s potential to develop into a productive, independent research or physician-scientist.
A Round of Applause for the School’s Current and Recent NRSA Fellows!
Waqar Arif (Biochemistry, MD/PhD), Lily Mahapatra (Biochemistry), Shannon Walsh (Biochemistry), Matthew Biehl (MIP), Robin Holland (Micro), Itamar Livnat (MIP), Bernard Slater (MIP), Daniel Harris (Biochemistry), Paven Aujla (MIP), Sumanprava Giri (CDB)
American Heart Association (AHA) Fellowships are granted to help initiate careers in cardiovascular and stroke research by providing research assistance and training. Awardees devote their time to research or activities directly related to their development into independent researchers.
Congratulations to the School’s Current AHA Fellows!
Donghyun Kim (MIP), AHA Postdoctoral Fellowship
Dennis Piehl (Biochemistry), AHA Predoctoral Fellowship
The Midwest Regional Chapter of the Society of Toxicology (MRC-SOT) provides an annual Young Investigator Award to individual research trainees in the area of the toxicological sciences. The purpose of the award is to ensure that an adequate number of highly trained scientists will be available to meet the future toxicology research needs. Young Investigator awardees will present the research at the following Annual Meeting of MRC-SOT.
Kirsten Eckstrum, from the department of Molecular and Integrative Physiology, received the 2015 Midwest RC Young Investigator Award at the 2015 Spring Meeting.
The Schlumberger Foundation Faculty for the Future Fellowship, which is awarded to women scientists and engineers from developing world to pursue postgraduate studies at leading universities worldwide. After completion of the study, individuals will return to their home countries where they will contribute to the development of science. In the 2015-2016 academic year, the Schlumberger Foundation awarded new fellowships to 155 women, and has also extended 135 existing grants.
Elizabeth Amosun, from Microbiology, received the Schlumberger Fellowship in 2015.
The Damon Runyon Research Foundation encourages all theoretical and experimental research relevant to the study of cancer including cancer causes, mechanisms, therapies and prevention. After successful completion of the fellowship, Damon Runyon Fellows are eligible to apply for the Dale F. Frey Award for Breakthrough Scientists, which provides additional support to exceptional Damon-Runyon Fellows.
Melanie Issigonis, a postdoctoral fellow in the Newmark Lab, received the Damon Runyon Cancer Research Foundation award in September of 2012.
Posted April 18, 2016
return to top
Prevalent but Under-studied Skin Infection Focus of New Research
Shisler, together with Dr. Brian Ward from the University of Rochester, will study the molluscum contagiosum virus (MCV) in detail to identify ways to regulate its underlying proteins to formulate cures for infections and diseases such as cancer.
According to the CDC, molluscum contagiosum is an infection caused by a poxvirus (molluscum contagiosum virus; MCV). It is one of the most common skin infections in children and sexually active young adults. Despite this common infection, one major hurdle is that the virus cannot be propagated in cell culture. Most other viruses, such as herpes viruses, can be grown in cultured cells, making them easier to study. The goal of this research is to use new approaches to understand what barriers cells create to prevent virus replication.
Molluscum contagiosum (MC) is usually a benign though unsightly, mild skin disease characterized by lesions (growths) that may appear anywhere on the body. Within 6-12 months, molluscum contagiosum typically resolves without scarring but may take as long as 4 years and can be associated with stigma and the anxiety it produces.
In people with weakened immune systems (i.e., HIV-infected persons or persons being treated for cancer), these lesions can become much larger and persist indefinitely. Long-term effects include scarring and secondary infections caused by bacteria. Secondary infections may be a significant problem in immunocompromised patients, such as those with HIV/AIDS or those taking immunosuppressing drug therapies.
“Viruses are one of the most abundant microorganisms on the planet, infecting every form of life from humans to bacteria. However, these are the microbes that we understand the least. By understanding how viruses hijack the host cell, researchers can begin to answer fundamental questions about virology including how we can engineer new methods to detect and cure infectious viruses,” said Shisler.
Posted January 11, 2016
return to top
Martha Gillette and collaborators receive two grants to study the brain
The work is facilitated by two grants that Gillette is a part of: the Emergent Behaviors of Integrated Cellular Systems (EBICS), which received $25 million in National Science Foundation (NSF) renewal funding for the next five years and the National Institute of Health (NIH) BRAIN Initiative grant which has received more than $2 million in funding over three years.
The goal of the EBICS project is to build living, multi-cellular machines to solve environmental, health, and security problems. These “biological machines” will serve as a basis to deliver drugs more effectively, function as internal diagnostic tools, or as contaminant sensors in the field. Gillette’s group focuses on developing neuronal circuits to provide sensing and processing for the biological machines (biobots).
The (NIH) Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative works towards developing tools to characterize and analyze the brain at the cell and even subcellular levels to show how individual cells and neural circuits interact with each other in time and space. Gillette currently works in Beckman’s NeuroTech Group and studies the brain’s plastic responses to experience, investigating signals that shape and wire the nervous system.